UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv238-iv255

2018

Volltextzugriff (PDF)

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Oncogene, 2013-10, Vol.32 (41), p.4861-4870

2013

Volltextzugriff (PDF)

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2019-05, Vol.30 (5), p.871-873

2019

Volltextzugriff (PDF)

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Annals of oncology, 2018-10, Vol.29 (10), p.2121-2128

2018

Volltextzugriff (PDF)

New molecular therapies for hepatocellular carcinoma

Clinics and research in hepatology and gastroenterology, 2015-09, Vol.39, p.S80-S85

2015

Volltextzugriff (PDF)

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

ESMO open, 2023-06, Vol.8 (3), p.101567-101567, Article 101567

2023

Volltextzugriff (PDF)

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Annals of oncology, 2022-06, Vol.33 (6), p.666-666

2022

Volltextzugriff (PDF)

Post-fire hydrological and erosional responses of a Mediterranean landscpe: Seven years of catchment-scale dynamics

Catena (Giessen), 2007-09, Vol.71 (1), p.68-75

2007

Volltextzugriff (PDF)

New aspects of diagnosis and therapy of hepatocellular carcinoma

Oncogene, 2006-06, Vol.25 (27), p.3848-3856

2006

Volltextzugriff (PDF)

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Annals of oncology, 2022-09, Vol.33, p.S1401

2022

Volltextzugriff (PDF)

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Seminars in liver disease, 1999, Vol.19 (3), p.329-338

1999

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Annals of oncology, 2018-10, Vol.29, p.viii208-viii208

2018

Volltextzugriff (PDF)

Next-Generation Sequencing: Path for Driver Discovery in Hepatocellular Carcinoma

Gastroenterology (New York, N.Y. 1943), 2012-11, Vol.143 (5), p.1391-1393

2012

Volltextzugriff (PDF)

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Annals of oncology, 2021-06, Vol.32 (6), p.801-805

2021

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2018-06, Vol.29, p.v122-v122

2018

Volltextzugriff (PDF)

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2019-07, Vol.30, p.iv133-iv133

2019

Volltextzugriff (PDF)

Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

European radiology, 2006-11, Vol.16 (11), p.2454-2462

2006

Volltextzugriff (PDF)

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

Hepatology (Baltimore, Md.), 2000-04, Vol.31 (4), p.1019-1021

2000

Volltextzugriff (PDF)

Obtaining industrial experimental designs using a heuristic technique

Expert systems with applications, 2011-08, Vol.38 (8), p.10094-10098

2011

Volltextzugriff (PDF)

Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma

JNCI : Journal of the National Cancer Institute, 2008-08, Vol.100 (16), p.1121-1123

2008

Volltextzugriff (PDF)

Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma

Hepatology (Baltimore, Md.), 2000-09, Vol.32 (3), p.678-680

2000

Volltextzugriff (PDF)

Hepatocellular carcinoma: is surveillance cost effective?

Gut, 2001-02, Vol.48 (2), p.149-150

2001

Volltextzugriff (PDF)

1057 PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL

Journal of hepatology, 2009, Vol.50, p.S385-S385

2009

Volltextzugriff (PDF)

P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress

Annals of oncology, 2021-07, Vol.32, p.S144-S145

2021

Volltextzugriff (PDF)

Updated treatment approach to hepatocellular carcinoma

Journal of gastroenterology, 2005-03, Vol.40 (3), p.225-235

Llovet, Josep M

2005

Volltextzugriff (PDF)

1 – 25 von 1.043

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(397)
Mit Volltextzugriff
(952)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(152)
Science & Technology
(143)
Life Sciences & Biomedicine
(113)
Male
(66)
Female
(63)
Middle Aged
(50)
Gastroenterology & Hepatology
(48)
Adult
(44)
Aged
(32)
Gastroenterology And Hepatology
(32)
Oncology
(31)
Hepatocellular Carcinoma
(30)
Liver Neoplasms - Pathology
(26)
Physical Sciences
(25)
Liver Cancer
(24)
Carcinoma, Hepatocellular - Pathology
(23)
Carcinoma, Hepatocellular - Therapy
(22)
Liver Neoplasms - Therapy
(21)
Prognosis
(21)
Liver Neoplasms - Genetics
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

New molecular therapies for hepatocellular carcinoma

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Post-fire hydrological and erosional responses of a Mediterranean landscpe: Seven years of catchment-scale dynamics

New aspects of diagnosis and therapy of hepatocellular carcinoma

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Next-Generation Sequencing: Path for Driver Discovery in Hepatocellular Carcinoma

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

Obtaining industrial experimental designs using a heuristic technique

Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma

Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma

Hepatocellular carcinoma: is surveillance cost effective?

1057 PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL

P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress

Updated treatment approach to hepatocellular carcinoma

Aktive Filter

Suchergebnisse filtern